SAN FRANCISCO, Nov. 1, 2018 /PRNewswire-PRWeb/ — uBiome, the leader in microbial genomics, announces the addition of Dr. Jobin, PhD, Gatorade Trust Professor of Medicine and Program Leader of Cancer Therapeutics & Host Response at the University of Florida Health Cancer Center, to its Scientific Advisory Board. Joining the board of leading scientists and doctors from around the world, Dr. Jobin will bring to uBiome over 20 years of experience studying host-microbe interactions and expertise in the role of microorganisms in cancer pathogenesis. The appointment will help uBiome continue its advancement in human microbiome research.

“Dr. Jobin’s groundbreaking research linking intestinal bacteria to patients’ response to immuno-therapeutic cancer treatment is very impressive,” Dr. Jessica Richman, PhD, co-founder and CEO of uBiome, said. “We are honored to have him as a scientific advisor.”

Dr. Jobin is a Gatorade Trust Professor of Medicine and Program Leader of Cancer Therapeutics & Host Response in the Division of Gastroenterology, Hepatology, and Nutrition at the University of Florida Health Cancer Center. The Jobin Lab studies the contribution of bacteria in protecting or exacerbating development of colitis and colorectal cancer using various genomic techniques and gnotobiotic technology. He has published numerous papers on innate signaling events taking place in the intestine and how these impact intestinal homeostasis. In addition to being the Associate Editor of Microbiome, he is a member of the American Gastroenterological Association, Mucosal Immunology Association, American Society for Biochemistry and Molecular Biology, and American Association of Immunologists.

About joining uBiome’s Scientific Advisory Board, Dr. Jobin said, “I am excited to join the advisory board of uBiome, a company at the leading edge of translational microbiome research.”

In addition to Dr. Jobin, the uBiome Scientific Advisory Board also includes Dr. Joseph DeRisi (MacArthur Genius and UCSF professor), Dr. Atul Butte (head of the Institute for Computational Health Sciences at UCSF), Dr. Katherine Pollard (Director, Gladstone Institute for Data Science and Biotechnology), Dr. Joel Palefsky (UCSF School of Medicine professor), Dr. George Church (leading geneticist at Harvard University), Dr. Liz Lipski (Academic Director of Nutrition and Integrative Health Programs at Maryland University of Integrative Health), Dr. Elaine Hsiao, PhD (UCLA), and other leading scientists. The company’s Medical Advisory Board includes Dr. Alan Green (Society for Participatory Medicine), Dr. Leo Treyzon (Cedars-Sinai Medical Center), Dr. Cynthia Geyer (Medical Director of Canyon Ranch, Lenox), Dr. Robynne Chutkan (Georgetown University Hospital), Michael Docktor (Boston Children’s Hospital), Dr. Tiffany Lester (Medical Director of Parsley Health in San Francisco), Dr. Joel Kahn (Founder of of the Kahn Center for Cardiac Longevity), as well as other accomplished clinicians.

_____
About uBiome
Founded in 2012, uBiome is the leader in microbial genomics. The Company’s mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets.

uBiome’s commercial products include SmartGut™, the world’s first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn’s Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women’s health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.

uBiome’s platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.

Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company’s Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.

SOURCE Ubiome